市場調查報告書
商品編碼
1466286
伴同性診斷市場:按技術、適應症和最終用戶分類 - 2024-2030 年全球預測Companion Diagnostics Market by Technology (Immunohistochemistry, In Situ Hybridization, Next-Generation Sequencing), Indication (Cancer, Cardiovascular Diseases, Infectious Diseases), End-user - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
伴同性診斷市場規模預計2023年為66.4億美元,2024年達73億美元,預計2030年將達到134.9億美元,複合年成長率為10.65%。
伴同性診斷是專門的測試,旨在幫助醫療保健專業人員確定特定的醫療程序對患者是否有效,並確定該個體的最佳劑量。這些測試是個人化醫療的重要組成部分,個人化醫療是一種根據每個患者的個人特徵(包括生活方式、遺傳傾向和環境)提供量身定做治療的醫療方法。伴同性診斷被廣泛使用,特別是在某些癌症的治療中,其中治療效果可能會受到腫瘤內存在的遺傳改變的極大影響。個人化醫療的發展,即根據患者個別情況最佳化治療,是伴同性診斷需求的主要驅動力。此外,標靶治療的開發,特別是在腫瘤學領域,需要伴同性診斷來識別將從這些治療中受益最多的患者。然而,開發和引入伴同性診斷的成本高昂,報銷不足是一個主要障礙。此外,次世代定序和數位 PCR 等技術正在擴展伴同性診斷的能力,並實現更全面的基因分析,為市場成長提供了巨大的機會。
主要市場統計 | |
---|---|
基準年[2023] | 66.4億美元 |
預測年份 [2024] | 73億美元 |
預測年份 [2030] | 134.9億美元 |
複合年成長率(%) | 10.65% |
科技 精準醫療領域對次世代定序儀的偏好日益增加
免疫組織化學 (IHC) 是一種透過檢測組織切片中細胞中的蛋白質來診斷疾病的技術。它廣泛用於癌症診斷,以識別有助於確定癌症類型及其對治療的潛在反應的特異性標記。當診斷重點是組織樣本中蛋白質表現的定位和定性評估時,首選 IHC。原位雜合技術 (ISH) 能夠檢測和定位組織切片或細胞樣本中的特定 DNA 或 RNA 序列,從而深入了解基因表現和染色體畸變。該技術在檢測與某些癌症相關的特定基因重排和擴增方面特別有用。次世代定序儀(NGS) 透過以前所未有的速度和規模對整個基因組或感興趣區域進行定序,提供對基因組成的全面洞察。 NGS 是需要廣泛了解遺傳變異(包括小突變、拷貝數變異等)的應用的首選技術,這些變異可能與多種疾病的標靶治療選擇相關。聚合酵素鏈鎖反應(PCR) 是一種用於增強 DNA 或 RNA 小片段以促進進一步分析的技術。 PCR 由於其簡單性、敏感性和特異性而成為最廣泛使用的技術之一。 PCR 因其快速處理時間而備受青睞,使其成為需要快速決策以選擇治療方法的疾病的理想選擇。
最終用戶製藥和生物製藥領域的擴展推動了伴同性診斷的重要性
製藥和生物製藥公司主要從事治療藥物的發現、開發和商業化。伴同性診斷的整合在標靶治療治療的開發過程中至關重要,特別是在癌症治療中。這些公司需要伴同性診斷來監測治療反應並根據需要調整治療計劃。參考文獻實驗室是執行複雜且先進的診斷測試的專業設施,而標準醫院實驗室通常無法提供這些測試。它們透過提供複雜的測試來幫助識別與特定疾病和治療反應相關的生物標記物,在實施伴同性診斷中發揮重要作用。
區域洞察
在美洲,強大的醫療基礎設施、日益增強的個人化醫療意識以及重要的研發活動推動了對伴同性診斷的需求。美國食品藥物管理局(FDA) 在核准癌症治療伴同性診斷方面特別積極,並強調了這些工具在治療決策中的重要性。該地區的投資和舉措主要集中在癌症、心血管疾病和神經病學領域,反映出個人化醫療解決方案的更廣泛趨勢。歐盟國家對伴同性診斷表現出很高的需求,並得到強力的法律規範促進創新,同時確保病人安全。歐洲藥品管理局 (EMA) 在整個歐洲核准伴同性診斷方面發揮關鍵作用。歐盟消費者的需求複雜,對個人化醫療服務抱有很高的期望。在阿拉伯聯合大公國和沙烏地阿拉伯等中東國家,在政府措施和醫療基礎設施投資的支持下,人們對個人化醫療的興趣與日俱增。然而,由於衛生基礎設施和服務有限,非洲面臨重大障礙。在亞太地區,在政府旨在普及醫療保健標準和促進個人化醫療的舉措的推動下,伴同性診斷市場正在迅速擴大。政府推出了多項推動精準醫療的舉措,包括對基因研究的大量投資。這種關注逐漸體現在對伴同性診斷不斷成長的需求上,尤其是在設備齊全的都市區。
FPNV定位矩陣
FPNV 定位矩陣對於評估伴同性診斷市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對伴同性診斷市場中供應商的現狀進行富有洞察力和深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4.競爭評估與資訊:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.伴同性診斷市場的市場規模和預測是多少?
2.在伴同性診斷市場的預測期間內,有哪些產品、細分市場、應用和領域需要考慮投資?
3.伴同性診斷市場的技術趨勢和法規結構是什麼?
4.伴同性診斷市場主要廠商的市場佔有率為何?
5.進入伴同性診斷市場的合適型態和策略手段是什麼?
[194 Pages Report] The Companion Diagnostics Market size was estimated at USD 6.64 billion in 2023 and expected to reach USD 7.30 billion in 2024, at a CAGR 10.65% to reach USD 13.49 billion by 2030.
Companion diagnostics are specialized tests designed to help healthcare professionals determine whether a particular medical treatment is effective for a patient or to identify the best dosage of medication for that individual. These tests are an integral part of personalized medicine, a medical approach that tailors treatment to the individual characteristics of each patient, such as their lifestyle, genetic makeup, and environment. Companion diagnostics are particularly prevalent in the management of certain cancers, where the effectiveness of the treatment can depend significantly on the genetic alterations present within the tumor. The push towards personalized medicine, where treatments are optimized for individual patient profiles, significantly drives the demand for companion diagnostics. Moreover, the development of targeted therapies, especially in oncology, necessitates companion diagnostics to identify patients who would most benefit from these treatments. However, the development and implementation of companion diagnostics can be costly, with inadequate reimbursement posing a significant barrier. Furthermore, technologies, including next-generation sequencing and digital PCR, are expanding the capabilities of companion diagnostics, allowing for more comprehensive genetic profiling poses significant opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 6.64 billion |
Estimated Year [2024] | USD 7.30 billion |
Forecast Year [2030] | USD 13.49 billion |
CAGR (%) | 10.65% |
Technology: Increasing preference of next-generation sequencing in precision medicine
Immunohistochemistry (IHC) is a technique used to diagnose diseases by detecting proteins in tissue section cells. It is widely employed in cancer diagnostics to identify specific markers that help in determining the type of cancer and its potential responsiveness to treatments. IHC is preferred when the diagnostic focus is on the localization and qualitative assessment of protein expressions in tissue samples. Situ Hybridization (ISH) permits the detection and localization of specific DNA or RNA sequences in tissue sections or cell samples, providing insights into gene expression and chromosomal abnormalities. This technology is particularly valuable in detecting specific gene rearrangements or amplifications associated with certain cancers. Next-generation sequencing (NGS) offers comprehensive insights into the genetic makeup by allowing the sequencing of entire genomes or targeted regions of interest at an unprecedented speed and scale. NGS is the technology of choice for applications requiring a broad understanding of genetic variations, including small mutations, copy number variations, and others that may be relevant for selecting targeted therapies across various diseases. Polymerase Chain Reaction (PCR) is a technique utilized to strengthen small segments of DNA or RNA, making it easier to conduct further analyses. It stands as one of the most widely used technologies due to its simplicity, sensitivity, and specificity. PCR is highly favored for its rapid turnaround times, making it ideal for diseases requiring quick decision-making for therapy selection.
End-user: Expansion of pharmaceutical and biopharmaceutical sector driving the significance of companion diagnostics
Pharmaceutical and biopharmaceutical companies engaged primarily in the discovery, development, and commercialization of therapeutics. The integration of companion diagnostics is crucial in the drug development process, especially for targeted therapies, including those used in cancer treatment. These companies need companion diagnostics to monitor responses to therapy and adjust treatment plans as necessary. Reference laboratories are specialized facilities that perform complex and advanced diagnostic testing, often not available in standard hospital labs. They play a critical role in the implementation of companion diagnostics by providing high-complexity tests that help in the identification of biomarkers associated with specific diseases and treatment responses.
Regional Insights
In the Americas, the demand for companion diagnostics is driven by a robust healthcare infrastructure, heightened awareness about personalized medicine, and significant research and development activities. The U.S. Food and Drug Administration (FDA) has been proactive in approving companion diagnostics, especially for cancer treatments, which underscores the importance of these tools in therapeutic decisions. Investments and initiatives in this region are primarily focused on oncology, cardiovascular diseases, and neurology, reflecting a broader trend toward personalized healthcare solutions. EU countries exhibit a high demand for companion diagnostics, supported by a strong regulatory framework that promotes innovation while ensuring patient safety. The European Medicines Agency (EMA) plays an vital role in the approval of companion diagnostics across Europe. Consumer needs in the EU are sophisticated, with a high expectation for personalized healthcare services. Middle Eastern countries, such as the United Arab Emirates and Saudi Arabia, are witnessing a growing interest in personalized medicine, which is supported by government initiatives and investments in healthcare infrastructure. Africa, however, faces significant hurdles due to limited healthcare infrastructure and access. In APAC, the market for companion diagnostics is expanding swiftly, fueled by government initiatives aimed at improving healthcare standards and embracing personalized medicine. The government has launched several initiatives to promote precision medicine, including significant investments in genetic research. This focus is gradually translating into increased demand for companion diagnostics, particularly in urban areas with better healthcare facilities.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Companion Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Companion Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Companion Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abnova Corporation, Agendia, Inc., Agilent Technologies, Inc., Almac Group, Amoy Diagnostics Co., Ltd., ARUP Laboratories, Bio-Techne Corporation, Biogenex Laboratories, Inc, bioMerieux SA, Danaher Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Guardant Health, Inc, ICON PLC, Illumina, Inc., Invivoscribe Technologies, Inc., Myriad Genetics, Inc., NG biotech, QIAGEN N.V., R-Biopharm AG, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Companion Diagnostics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Companion Diagnostics Market?
3. What are the technology trends and regulatory frameworks in the Companion Diagnostics Market?
4. What is the market share of the leading vendors in the Companion Diagnostics Market?
5. Which modes and strategic moves are suitable for entering the Companion Diagnostics Market?